Status and phase
Conditions
Treatments
About
A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.
Full description
This is a phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 administered intravenously in participants with Early Alzheimer's Disease.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
381 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Study Lead
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal